The Composite measure OCM-4 consists of two measures: OCM-4a (MIPS 143 and NQF 0384) and OCM-4b (NQF 0383).

Note: This version of the OCM-4a Measure Specifications is to be used for reporting for the measurement period beginning 07/01/2019 and future measurement periods. If an updated version of this document is released, this version will be used for reporting until the effective date of the new version.

Disclaimer: Please note that this measure was adapted from an NQF-endorsed measure; the measure specifications were changed for use in the Oncology Care Model. NQF has not reviewed or approved the revised measure specifications.

**SUMMARY OF CHANGES FROM MIPS 143 SPECIFICATIONS**

- Remove 1125F with 8P. This code is used in the MIPS program to support pay-for-reporting.
- Updated codes used for the qualifying provider encounter and chemotherapy (see “OCM Tech Spec Value Set” for specific codes).
- The Denominator and Numerator criteria were not divided into two sets of criteria—one for radiation and one for chemotherapy—as dividing them does not alter the calculations or measure results.

**Important Note:** Please refer to the OCM Quality Measures Guide sections 2.1 and 3.3.2 for additional OCM-specific reporting requirements applicable to the OCM encounter-based measures.

**Description**

Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified

**Measure Scoring**

Proportion

**Measure Type**

Process

**Improvement Notation**

Higher score indicates better quality
Oncology Care Model Measure Specifications

**Definitions**
None

**Guidance**
This measure is to be reported once per qualifying provider encounter for qualifying patients.

It is anticipated that clinicians providing care for patients with cancer will submit this measure.

**NOTE:** For patients receiving radiation therapy, pain intensity should be quantified at each radiation treatment management encounter. Due to the nature of some applicable coding related to the radiation therapy (e.g., delivered in multiple fractions), the billing date for certain codes may or may not be the same as the face-to-face encounter date. For patients receiving chemotherapy, pain intensity should be quantified at each face-to-face encounter with the physician while the patient is currently receiving chemotherapy. For purposes of identifying eligible encounters, patients “currently receiving chemotherapy” refers to patients administered chemotherapy within 30 days prior to the encounter AND administered chemotherapy within 30 days after the date of the encounter.

**Numerator Instructions:**
Pain intensity should be quantified using a standard instrument, such as a 0-10 numerical rating scale, visual analog scale, a categorical scale, or the pictorial scale. Examples include the Faces Pain Rating Scale and the Brief Pain Inventory (BPI).

**Initial Population**
Not Applicable

**Denominator**
All patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy

**DENOMINATOR NOTES:**
Provider encounters with telehealth modifiers of GQ, GT, 95 or POS 02 will not be included in this measure.
For the reporting purposes for this measure, in instances where CPT code 77427 is reported, the billing date, which may or may not be the same date as the face-to-face encounter with the physician, should be used to pull the appropriate patient population into the denominator. It is expected, though, that the numerator criteria would be performed at the time of the actual face-to-face encounter during the series of treatments.
## Oncology Care Model Measure Specifications

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
</table>
| **Step 1** | Active diagnosis of cancer during the qualifying provider encounter | - Cancer Diagnosis  
- Cancer Diagnosis Start Date  
- Cancer Diagnosis End Date  
- Encounter Date | - OCM Cancer Diagnosis |
| **Step 2** | Qualifying radiation treatment management encounter for radiation therapy during the measurement period  
OR  
Qualifying provider encounter (without telehealth modifiers GQ, GT, 95 or POS 02) during the measurement period  
AND  
Chemotherapy administration starts \( \leq 30 \) days before the end of the qualifying provider encounter AND starts \( \leq 30 \) days after the end of the qualifying provider encounter | - Radiation Treatment Management Encounter  
- Radiation Treatment Management Encounter Date  
- Encounter  
- Encounter Date  
- Chemotherapy  
- Chemotherapy Date  
- Measurement Period Start Date  
- Measurement Period End Date | - OCM Radiation Treatment Management Encounter  
- OCM Encounter  
- OCM 4 Chemotherapy |

### Denominator Exclusions
None

### Numerator
Patient visits in which pain intensity is quantified

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
</table>
| **Step 1** | Pain intensity quantified during qualifying provider encounter | - Pain Intensity Quantified Pain Present  
- Pain Intensity Quantified Pain Present Date  
- Pain Intensity Quantified No Pain  
- Pain Intensity Quantified No Pain Date  
- Radiation Treatment Management Encounter  
- Radiation Treatment Management Encounter Date  
- Encounter  
- Encounter Date | - OCM Pain Intensity Quantified Pain Present  
- OCM Pain Intensity Quantified No Pain  
- OCM Radiation Treatment Management Encounter  
- OCM Encounter |
Oncology Care Model Measure Specifications

Denominator Exceptions
None

Numerator Exclusions
Not Applicable

Risk Adjustment
None

Rationale
Initial and ongoing pain assessments are essential to ensure proper pain management among patients with cancer. An inadequate assessment of pain is linked to poor pain control. Unrelieved pain has a significant impact on patients’ quality of life, denying them comfort and greatly affecting their activities, motivation, and interactions with family and friends. Additionally, there is growing evidence that cancer survival is associated with effective pain management. (NCCN, 2016)

Clinical Recommendation Statements
− All patients must be screened for pain at each contact.
− Pain intensity must be quantified and quality must be characterized by the patient (whenever possible based on patient communication capacity).
− Comprehensive pain assessment must be performed if new or worsening pain is present and regularly performed for persisting pain.
− Pain assessment is essential including patient reporting of qualities of the pain, breakthrough pain, treatments used and their impact on pain, patient reporting of adequate comfort, satisfaction with pain relief, provider assessment of impact on function, and any special issues for the patient relevant to pain treatment. If necessary, get additional information from the family/caregiver regarding pain and impact on function.
− Evaluate the patient for risk factors of opioid abuse/misuse/diversion. (Category 2A) (NCCN, 2017)
− Various methods and tools exist to assess pain severity. Intensity of pain should be quantified using a numerical rating scale (i.e., 0-10), visual analog scale, categorical scale, or pictorial scale (eg, The Faces Pain Rating Scale). (Category 2A) (NCCN, 2017)

References

Oncology Care Model Measure Specifications


**Copyright**

The Measure is not a clinical guideline, does not establish a standard of medical care, and has not been tested for all potential applications.

The Measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain.

Commercial uses of the Measure require a license agreement between the user and the PCPI® Foundation (PCPI®) or the American Medical Association (AMA). Neither the AMA, nor the former AMA-convened Physician Consortium for Performance Improvement® (AMA-PCPI), nor PCPI, nor their members shall be responsible for any use of the Measure.

AMA and PCPI encourage use of the Measure by other health care professionals, where appropriate.

**THE MEASURE AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.**

© 2018 PCPI® Foundation and American Medical Association. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the PCPI and its members and former members of the AMA-PCPI disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measure specifications is copyright 2004-2018 American Medical Association. LOINC® is copyright 2004-2018 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms® (SNOMED CT®) copyright 2004-2018 International Health Terminology Standards Development Organisation. ICD-10 is copyright 2018 World Health Organization. All Rights Reserved.
Oncology Care Model Measure Specifications

Note: This version of the OCM-4a Measure Flow is to be used for reporting for the measurement period beginning 07/01/2019 and future measurement periods. If an updated version of this document is released, this version will be used for reporting until the effective date of the new version.
1. For OCM FFS Beneficiary Aggregate Reporting:
   a. If patient is a Qualifying OCM FFS Beneficiary as Defined in Section 2.1 of the “OCM Quality Measures Guide,” and meets the additional OCM-specific reporting requirements applicable to the OCM encounter-based measures as described in Section 3.3.2, include the patient in aggregate results that are reported in the OCM Data Registry. Proceed to check Patient Diagnosis of Cancer.
   b. If patient is not a Qualifying OCM FFS Beneficiary as Defined in Section 2.1 of the “OCM Quality Measures Guide,” stop processing. Patient does not qualify as an OCM FFS Beneficiary and should not be included in aggregate results that are reported to the OCM Data Registry.

2. Check Patient Diagnosis of Cancer:
   a. If Active Diagnosis of Cancer During Qualifying Provider Encounter equals No, do not include in Denominator. Stop processing.

3. Check Qualifying Radiation Treatment Management Encounter:
   a. If Qualifying Radiation Treatment Management Encounter for Radiation Therapy During Measurement Period equals Yes, include in Denominator. Proceed to check Pain Intensity Quantified.
   b. If Qualifying Radiation Treatment Management Encounter for Radiation Therapy During Measurement Period equals No, check Qualifying Provider Encounter.

4. Check Qualifying Provider Encounter:
   a. If Qualifying Provider Encounter (without Telehealth Modifiers GQ, GT, 95 or POS 02) During Measurement Period equals No, do not include in Denominator. Stop processing.
   b. If Qualifying Provider Encounter (without Telehealth Modifiers GQ, GT, 95 or POS 02) During Measurement Period equals Yes, check Chemotherapy.

5. Check Chemotherapy:
   a. If Chemotherapy Starts <= 30 Days Before End of Qualifying Provider Encounter and Starts <= 30 Days After End of Qualifying Provider Encounter equals No, do not include in Denominator. Stop processing.
Oncology Care Model Measure Specifications

b. If Chemotherapy Starts <= 30 Days Before End of Qualifying Provider Encounter and Starts <= 30 Days After End of Qualifying Provider Encounter equals Yes, include in Denominator. Proceed to check Pain Intensity Quantified.

6. Check Pain Intensity Quantified:

a. If Pain Intensity Quantified During Qualifying Provider Encounter equals Yes, include in Numerator. Stop processing.

b. If Pain Intensity Quantified During Qualifying Provider Encounter equals No, do not include in Numerator. Stop processing.